Skip to content

Annexon ANNX Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.33M+91.4%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$6.67M+43.8%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$5.77M+396%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$437K+90.9%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$2.03M-217%
Alumis Inc. logo
Alumis Inc.ALMS
-$9.72M-295%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's change in accrued liabilities?
Annexon (ANNX) reported change in accrued liabilities of -$9.4M in Q1 2026.
How has Annexon's change in accrued liabilities changed year-over-year?
Annexon's change in accrued liabilities decreased by 421.2% year-over-year, from $2.93M to -$9.4M.
What is the long-term trend for Annexon's change in accrued liabilities?
Over 2 years (2021 to 2024), Annexon's change in accrued liabilities has grown at a 207.1% compound annual growth rate (CAGR), from $773K to $7.29M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.